MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab

Key Takeaways MRNA will get up to $54.3M from CEPI to run a pivotal phase III study of its mRNA-1018 H5 flu vaccine.Moderna's phase III will test safety and immunogenicity in the U.S. and U.K., starting in early 2026.MRNA plans to set aside 20% of H5 vaccine output for low and middle-income countries if approved.Moderna (MRNA) announced that the Coalition for Epidemic Preparedness Innovations (“CEPI”) will invest up to $54.3 million in funding to support a pivotal phase III study evaluating its investigatio ...